185 related articles for article (PubMed ID: 35034375)
1. Plateletcrit for predicting prognosis in patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloid.
Tu H; Li M; Chen Z; Zhao J; Wang H; Qian J; Wei C; Yang Y; Zhu Y; Zuo L
J Clin Lab Anal; 2022 Feb; 36(2):e24240. PubMed ID: 35034375
[TBL] [Abstract][Full Text] [Related]
2. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome.
Gao H; Ruan JQ; Chen J; Li N; Ke CQ; Ye Y; Lin G; Wang JY
Drug Des Devel Ther; 2015; 9():4861-8. PubMed ID: 26346783
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study.
Liu F; Rong X; Guo H; Xu D; Liu C; Meng L; Yang X; Guo T; Kan X; Song Y
BMC Gastroenterol; 2020 Feb; 20(1):30. PubMed ID: 32019495
[TBL] [Abstract][Full Text] [Related]
4. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Zhuge Y; Liu Y; Xie W; Zou X; Xu J; Wang J;
J Gastroenterol Hepatol; 2019 Apr; 34(4):634-642. PubMed ID: 30669184
[TBL] [Abstract][Full Text] [Related]
5. Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Wang X; Zhang W; Zhang M; Zhang F; Xiao J; Yin Q; Han H; Li T; Lin G; Zhuge Y
Hepatol Int; 2022 Jun; 16(3):669-679. PubMed ID: 35023026
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome.
Kan X; Ye J; Rong X; Lu Z; Li X; Wang Y; Yang L; Xu K; Song Y; Hou X
Sci Rep; 2016 Nov; 6():37998. PubMed ID: 27897243
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathological analysis of 16 cases of pyrrolizidine alkaloids-associated hepatic sinusoidal obstruction syndrome].
Li YS; Bao J; Xu Y; Wang TL
Zhonghua Gan Zang Bing Za Zhi; 2020 Apr; 28(4):332-337. PubMed ID: 32403886
[No Abstract] [Full Text] [Related]
8. Tusanqi and hepatic sinusoidal obstruction syndrome.
Wang JY; Gao H
J Dig Dis; 2014 Mar; 15(3):105-7. PubMed ID: 24528632
[TBL] [Abstract][Full Text] [Related]
9. Gadoxetic Acid-Enhanced Hepatobiliary-Phase Magnetic Resonance Imaging for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome and Association with Liver Function.
Guo T; Li X; Yang X; Kong X; Liu H; Bai T; Xu K; Ye J; Song Y
Sci Rep; 2019 Feb; 9(1):1231. PubMed ID: 30718698
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparin in the treatment of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: five case reports.
Jiang M; Wang L; Du X; Hao M; Gao P
J Int Med Res; 2020 Sep; 48(9):300060520961916. PubMed ID: 32993424
[TBL] [Abstract][Full Text] [Related]
11. Timing and efficacy of transjugular intrahepatic portosystemic shunt in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Wu F; Yu J; Gan H; Zhang H; Tian D; Zheng D
Sci Rep; 2021 Nov; 11(1):21743. PubMed ID: 34741082
[TBL] [Abstract][Full Text] [Related]
12. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids.
Gao H; Li N; Wang JY; Zhang SC; Lin G
J Dig Dis; 2012 Jan; 13(1):33-9. PubMed ID: 22188914
[TBL] [Abstract][Full Text] [Related]
13. Histological evaluation of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: Correlation with Drum Tower Severity Scoring.
Li R; Li L; Cai Z; Chen J; Zhang H; Zhao S; Tu J; Sun C; Jin Y; Zhang M; Zhang F; Zhang W; Yin Q; Xu H; Han H; Li T; Zhuge Y; Xiao J
Dig Liver Dis; 2024 Jul; 56(7):1220-1228. PubMed ID: 38151450
[TBL] [Abstract][Full Text] [Related]
14. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.
Yang XQ; Ye J; Li X; Li Q; Song YH
World J Gastroenterol; 2019 Jul; 25(28):3753-3763. PubMed ID: 31391770
[TBL] [Abstract][Full Text] [Related]
15. Prognostic risk factors for patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids.
Du X; Liu Z; Yu H; Wang Y; Zou Z; Wei H; Liang J; Yang D; Liu Y; Zhang J; Pan CQ
Medicine (Baltimore); 2023 Aug; 102(32):e34698. PubMed ID: 37565875
[TBL] [Abstract][Full Text] [Related]
16. [Study of PA-HSOS severity grading to predict the prognosis of patients with PA-HSOS treated by transjugular intrahepatic portosystemic shunt].
Chen YR; Zhang W; Zhang M; Zhang F; Xiao JQ; Yin Q; Zhuge YZ
Zhonghua Gan Zang Bing Za Zhi; 2021 Jan; 29(1):46-53. PubMed ID: 33541023
[No Abstract] [Full Text] [Related]
17. Enoxaparin attenuates pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome by inhibiting oncostatin M expression.
Xiang H; Liu C; Xiao Z; Du L; Wei N; Liu F; Song Y
Liver Int; 2023 Mar; 43(3):626-638. PubMed ID: 36354295
[TBL] [Abstract][Full Text] [Related]
18. Mid- to long-term outcomes of initial transjugular intrahepatic portosystemic shunt versus anticoagulation for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
Huang Q; Zhang Q; Xu H; Zu M; Xiao J; Shen B
Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):445-452. PubMed ID: 36719828
[TBL] [Abstract][Full Text] [Related]
19. Gynura Rhizoma containing pyrrolizidine alkaloids induces the hepatic sinusoidal obstruction syndrome in mice via upregulating fibrosis-related factors.
Zhang F; Zhou Y; Yang X; Xiong AZ; Wang ZT; Yang L
Acta Pharmacol Sin; 2019 Jun; 40(6):781-789. PubMed ID: 30367152
[TBL] [Abstract][Full Text] [Related]
20. Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt.
Xiao J; Tu J; Zhang H; Zhang F; Zhang W; Xu H; Yin Q; Yang J; Han H; Wang Y; Zhang B; Peng C; Zou X; Zhang M; Zhuge Y
Hepatol Int; 2021 Jun; 15(3):720-729. PubMed ID: 33507485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
